Companies and investors should disregard initial post-IPO market volatility. According to Robinhood's CFO, the true measure of a successful public offering isn't apparent for three, five, or even ten years. The key is to maintain a long-term focus on building customer value.

The traditional IPO exit is being replaced by a perpetual secondary market for elite private companies. This new paradigm provides liquidity for investors and employees without the high costs and regulatory burdens of going public. This shift fundamentally alters the venture capital lifecycle, enabling longer private holding periods.

In the 1980s, companies like Apple went public early as a fundraising necessity, allowing public investors to capture most of the growth. Today, robust private markets mean companies stay private longer, making IPOs primarily a liquidity event for insiders and VCs, with less upside left for the public.

For highly-capitalized companies like SpaceX and OpenAI, bankers are designing new IPO structures. Instead of standard 90-180 day lockup periods, they're planning staggered share releases over a longer timeframe to manage immense selling pressure from a large base of private shareholders and prevent post-IPO stock volatility.

The paper wealth generated on IPO day is a misleading metric due to lockup periods and market volatility. A more accurate mental model for an investor's actual return is the company's market capitalization 18 months after the public offering. This timeframe provides a truer 'locked in value' after initial hype and selling pressure subsides.

Reddit accepted a valuation haircut for its IPO, pricing shares at $34 versus a previous $61 peak. This strategy creates upward momentum, makes new investors and employees happy, and acts as powerful marketing, despite the initial dilution cost.

For trillion-dollar private companies like SpaceX going public, the traditional 90-180 day lockup period is inadequate. The massive volume of insider shares hitting the market at once could crash the stock. Investment bankers are now designing staggered lockup releases to manage this unprecedented liquidity event.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.

Contrary to the traditional focus on institutional investors, allocating a significant portion of an IPO to retail investors creates a loyal shareholder base. This "retail following" can result in higher valuation multiples and sustained brand advocacy, turning customers into long-term owners and a strategic asset.